File(s) under permanent embargo
Bertilimumab (Cambridge Antibody Technology Group)
journal contributionposted on 2023-05-26, 10:28 authored by Ding, C, Li, J, Zhang, X
Cambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.
Publication titleCurrent Opinion in Investigational Drugs